Advertisement

Pharmaceutical Applications of Finely Dispersed Systems

  • H. William Bosch
Chapter

Introduction

Pharmaceutical dosage forms comprise active agents (therapeutics or diagnostics) in a variety of physical forms including rigid (crystalline or amorphous) solids, liquids, homogeneous solutions, micellar solutions, emulsions, lipid complexes, and polymer complexes to name a few. The form in which the active agent is present depends on the physical and chemical characteristics of the agent, such as solubility and melting point as well as the intended route of administration. Fine-particle active agents (defined as having volume mean diameters of approximately 10 μm or less) have been incorporated into finished dosage forms for more than 30 years. The use of active agent nanoparticles in pharmaceutical products has appeared more recently and is a rapidly growing area of interest. This manuscript will discuss the preparation of fine-particle active agents and their uses in pharmaceutical dosage forms for oral, parenteral, and pulmonary administration and will be primarily...

Keywords

Active Agent Drug Substance Drug Particle Beclomethasone Dipropionate Mass Median Aerodynamic Diameter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    R.J. Lantz, Jr., in Pharmaceutical Dosage Forms: Tablets, Volume 2, Marcel Dekker, New York (1990) 117.Google Scholar
  2. 2.
    2. R.H. Müller, C. Jacobs, O. Kayser, Adv. Drug Deliv. Rev. 47 (2001) 3.CrossRefPubMedGoogle Scholar
  3. 3.
    H.W. Bosch, D.M. Marcera, R.L. Mueller, J.R. Swanson, D.S. Mishra, U.S. Patent No. 5,510,118 (1996).Google Scholar
  4. 4.
    J.R. Swanson, H.W. Bosch, K.J. Illig, D.M. Marcera, R.L. Mueller, U.S. Patent No. 5,543,133 (1996).Google Scholar
  5. 5.
    R.J. Lantz, Jr., in Pharmaceutical Dosage Forms: Tablets, Volume 2, Marcel Dekker, New York (1990) 123.Google Scholar
  6. 6.
    G.G. Liversidge, K.C. Cundy, J.F. Bishop, D.A. Czekai, U.S. Patent No. 5,145,684 (1992).Google Scholar
  7. 7.
    J.A. Bruno, B.D. Doty, E. Gustow, K.J. Illig, N. Rajagopalan, P. Sarpotdar, U.S. Patent No. 5,518,187 (1996).Google Scholar
  8. 8.
    8. E. Matijević, Chem. Mater. 5 (1993) 412.CrossRefGoogle Scholar
  9. 9.
    R.E. Sievers, U. Karst, U.S. Patent No. 6,095,134 (2000).Google Scholar
  10. 10.
    10. S. D. Škapin, E. Matijević, J. Colloid Interface Sci. 272 (2004) 90.CrossRefPubMedGoogle Scholar
  11. 11.
    11. L. Joguet, E. Matijević, J. Colloid Interface Sci. 250 (2002) 503.CrossRefPubMedGoogle Scholar
  12. 12.
    12. F. Ruch, E. Matijević, J. Colloid Interface Sci. 229 (2000) 207.CrossRefPubMedGoogle Scholar
  13. 13.
    13. H.W. Bosch, S. Škapin, E. Matijević, Colloids Surf. A Physicochem. Eng. Aspects 250 (2004) 43.CrossRefGoogle Scholar
  14. 14.
    Fosamax® (alendronate sodium tablets), Merck, in Physicians' Desk Reference®, 58 Edition, Thomson PDR, Montvale, NJ (2004) 1990.Google Scholar
  15. 15.
    15. A. Noyes, W.R. Whitney, J. Am. Chem. Soc. 19 (1897) 930.CrossRefGoogle Scholar
  16. 16.
    J.D. Pruitt, N.P. Ryde, American Association of Pharmaceutical Scientists, Annual Meeting and Exposition, Baltimore, MD (2004).Google Scholar
  17. 17.
    17. L.F. Prescott, R.F. Steel, W.R. Ferrier, Clin. Pharmacol. Ther. 11 (1970) 496.CrossRefPubMedGoogle Scholar
  18. 18.
    18. G.G. Liversidge, K.C. Cundy, Int. J. Pharm 125 (1995) 91.CrossRefGoogle Scholar
  19. 19.
    Megace ES® (megestrol acetate), Par Pharmaceutical, in PDR® Electronic Library, Thomson Micromedex, Greenwood Village, CO (2006).Google Scholar
  20. 20.
    Tricor® (fenofibrate tablets), Abbott Laboratories, in Physicians' Desk Reference®, 58 Edition, Thomson PDR, Montvale, NJ (2004) 522.Google Scholar
  21. 21.
    U. S. Food and Drug Administration, Center for Drug Evaluation and Research, NDA 019304, supplement no. 001, action date 02/09/1998.Google Scholar
  22. 22.
    U. S. Food and Drug Administration, Center for Drug Evaluation and Research, NDA 021203, supplement no. 000, action date 09/04/2001.Google Scholar
  23. 23.
    U. S. Food and Drug Administration, Center for Drug Evaluation and Research, NDA 021656, supplement no. 000, action date 11/05/2004.Google Scholar
  24. 24.
    U. S. Food and Drug Administration, Center for Drug Evaluation and Research, NDA 021695, supplement no. 000, action date 11/30/2004.Google Scholar
  25. 25.
    U. S. Food and Drug Administration, Center for Drug Evaluation and Research, NDA 021350, supplement no. 000, action date 05/07/2005.Google Scholar
  26. 26.
    Mobic® (meloxicam), Boehringer Ingelheim Pharmaceuticals, in Physicians' Desk Reference®, 58 Edition, Thomson PDR, Montvale, NJ (2004) 1017.Google Scholar
  27. 27.
    J.D. Pruitt, American Association of Pharmaceutical Scientists, Annual Meeting and Exposition, Salt Lake City, UT (2003).Google Scholar
  28. 28.
    H.W. Bosch, E.R. Cooper, S.L. McGurk, U. S. Patent No. 6,428,814 (2002).Google Scholar
  29. 29.
    S.B. Ruddy, W.M. Eickhoff, G. Liversidge, M.E. Roberts, U.S. Patent No. 5,593,657 (1997).Google Scholar
  30. 30.
    The United States Pharmacopeia (USP 26/NF 21), The United States Pharmacopeial Convention, Rockville, MD (2003) 1471.Google Scholar
  31. 31.
    Taxotere® (docetaxel), Sanofi‐Aventis, in PDR® Electronic Library, Thomson Micromedex, Greenwood Village, CO (2006).Google Scholar
  32. 32.
    32. E. Merisko-Liversidge, G.G. Liversidge, E.R. Cooper, Eur. J. Pharm. Sci. 18 (2003) 113.CrossRefPubMedGoogle Scholar
  33. 33.
    J.P. Donnelly, J.W. Mouton, N.M.A. Blijlevens, A. Smiets, P.E. Verweij, B.E. Depauw, American Society for Microbiology, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL (2001).Google Scholar
  34. 34.
    L.R. Cantilena, Jr., unpublished results.Google Scholar
  35. 35.
    G.G. Liversidge, E.R. Cooper, J.M. Shaw, G.L. McIntire, U. S. Patent No. 5,318,767 (1994).Google Scholar
  36. 36.
    G. Wolf, U.S. Patent No. 5,496,536 (1996).Google Scholar
  37. 37.
    A.J. Hickey, in Modern Pharmaceutics, G.S. Banker, C.T. Rhodes (eds.). Marcel Dekker, New York (2002) 480.Google Scholar
  38. 38.
    Pulmicort Turbuhaler 200 mcg (budesonide inhalation powder), AstraZeneca LP, in Physicians' Desk Reference®, 58 Edition, Thomson PDR, Montvale, NJ (2004) 642.Google Scholar
  39. 39.
    Flovent® Rotadisk® (fluticasone propionate inhalation poweder), GlaxoSmithKline, in Physicians' Desk Reference®, 58 Edition, Thomson PDR, Montvale, NJ (2004) 1507.Google Scholar
  40. 40.
    40. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, R. Langer, Science 276 (1997) 1868.CrossRefPubMedGoogle Scholar
  41. 41.
    H.W. Bosch, American Association of Pharmaceutical Scientists, Annual Meeting and Exposition, New Orleans, LA (1999).Google Scholar
  42. 42.
    42. K.D. Ostrander, H.W. Bosch, D.M. Marcera, Eur. J. Pharm. Biopharm. 48 (1999) 207.CrossRefPubMedGoogle Scholar
  43. 43.
    H.W. Bosch, D.M. Bondanza, R.A. Caspar, D.L. Gardner, F.A. Leith, International Society for Aerosols in Medicine Focus Symposium, Tours, France (1996).Google Scholar
  44. 44.
    44. C. Lipinski, Am. Pharm. Rev. 5 (2002) 82.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Elan Pharmaceutical TechnologiesKing of PrussiaUSA

Personalised recommendations